Identification of novel markers for uncomplicated lower genital tract infections and upper genital tract pathology due to Chlamydia trachomatis

Collet, Trudi; Macnaughton, Thomas B.; Walsh, Tamara; Debattista, Joseph

doi:10.1016/j.ijid.2010.12.005

Cited by 6 publications

(4 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…P-type ATPases constitute a superfamily of cation transport enzymes that mediate transmembrane exchange of all biologically significant cations [27]. In contrast, HSP70 is associated with outer membrane complexes of EBs and was originally thought to play a role in either attachment or entry of the EB into host cells [28, 29]. It is suggested that HSP70 indeed confers a humoral antibody response.…”

Section: Resultsmentioning

confidence: 99%

Unveiling New Molecular Factors Useful for Detection of Pelvic Inflammatory Disease due toChlamydia trachomatisInfection

Rodríguez-Cerdeira

Sánchez-Blanco

Molares-Vila

et al. 2012

ISRN Obstetrics and Gynecology

View full text Add to dashboard Cite

Background. Untreated Chlamydia trachomatis infections in women can result in disease sequelae such as pelvic inflammatory disease (PID), ultimately culminating in tubal occlusion and infertility. While nucleic acid amplification tests can effectively diagnose uncomplicated lower genital tract infections, they are not suitable for diagnosing upper genital tract pathological sequelae. Objective. The purpose of this paper was to provide a comprehensive review of new molecular factors associated with the diagnosis and prognosis of PID. Material and Methods. The literature was searched using the key words “Chlamydia trachomatis infections,” “pelvic inflammatory disease,” and “molecular factors” in the PubMed database. Relevant articles published between 1996 and 2012 were evaluated. Conclusions. The use of new molecular factors could potentially facilitate earlier diagnosis and prognosis in women with PID due to C. trachomatis infection.

show abstract

Section: Resultsmentioning

confidence: 99%

Unveiling New Molecular Factors Useful for Detection of Pelvic Inflammatory Disease due toChlamydia trachomatisInfection

Rodríguez-Cerdeira

Sánchez-Blanco

Molares-Vila

et al. 2012

ISRN Obstetrics and Gynecology

View full text Add to dashboard Cite

show abstract

“…Still, studies evaluating the diagnostic potential of the Medac cHSP60 ELISA test have revealed conflicting results, thus the ability of this assay to distinguish various C. trachomatis disease stages may be limited [ 169 , 170 ]. Australian study by Collet et al demonstrated that the use of four chlamydial antigens (CT157, CT423, CT727, and CT396) could potentially facilitate earlier diagnoses in women suffering from tubal occlusion and other pathologies of the upper genital tract [ 171 ]. They were found to be capable of discriminating between the infection and disease sequelae, such as tubal infertility.…”

Section: Laboratory Diagnosismentioning

confidence: 99%

Chlamydia trachomatisand Genital Mycoplasmas: Pathogens with an Impact on Human Reproductive Health

Ljubin‐Sternak

Meštrović²

2014

Journal of Pathogens

View full text Add to dashboard Cite

The most prevalent, curable sexually important diseases are those caused by Chlamydia trachomatis (C. trachomatis) and genital mycoplasmas. An important characteristic of these infections is their ability to cause long-term sequels in upper genital tract, thus potentially affecting the reproductive health in both sexes. Pelvic inflammatory disease (PID), tubal factor infertility (TFI), and ectopic pregnancy (EP) are well documented complications of C. trachomatis infection in women. The role of genital mycoplasmas in development of PID, TFI, and EP requires further evaluation, but growing evidence supports a significant role for these in the pathogenesis of chorioamnionitis, premature membrane rupture, and preterm labor in pregnant woman. Both C. trachomatis and genital mycoplasmas can affect the quality of sperm and possibly influence the fertility of men. For the purpose of this paper, basic, epidemiologic, clinical, therapeutic, and public health issue of these infections were reviewed and discussed, focusing on their impact on human reproductive health.

show abstract

“…Current research [34] involves the evaluation of chlamydial antigens (CT157, CT423, CT727, and CT396) to help in differentiation between lower genital infection and upper genital disorder from C. trachomatis. A number of potential markers for PID are under research, including pentraxin 3, E-cadherin, myeloperoxidase, stromal cell-derived factor 1, and the matrix metalloproteinase-9/matrix metalloproteinase-2 ratio [35 & ].…”

Section: Diagnosismentioning

confidence: 99%

Pelvic inflammatory disease in the adolescent

Greydanus

Dodich²

2015

Current Opinion in Pediatrics

View full text Add to dashboard Cite

Sequelae can be reduced in adolescent women if clinicians continue with regular chlamydia screening in sexually active adolescent women, have a low index of suspicion for pelvic inflammatory disease, carefully follow accepted treatment protocols, and teach youth comprehensive sexuality education including regular condom use. Funded research is needed to develop improved diagnosis and management tools as well as a chlamydia vaccine.

show abstract

Identification of novel markers for uncomplicated lower genital tract infections and upper genital tract pathology due to Chlamydia trachomatis

Abstract: The use of these assays could potentially facilitate earlier diagnoses in women suffering UGT pathology due to C. trachomatis.

Cited by 6 publications

References 23 publications

Unveiling New Molecular Factors Useful for Detection of Pelvic Inflammatory Disease due toChlamydia trachomatisInfection

Unveiling New Molecular Factors Useful for Detection of Pelvic Inflammatory Disease due toChlamydia trachomatisInfection

Chlamydia trachomatisand Genital Mycoplasmas: Pathogens with an Impact on Human Reproductive Health

Pelvic inflammatory disease in the adolescent

Contact Info

Product

Resources

About